NCT03894592

Brief Summary

This will be a pilot study utilizing Virtual Reality Analgesia (VRA) as a first line nonpharmacologic analgesic intervention on the Acute Rehabilitation Unit. In order to assess the efficacy of the intervention with a set of outcome measures will be defined:

  • Pain will be measured using the VAS for all subjects pre-, during and post-intervention via self-report.
  • Number of opioids/oral pain medication consumed will be analyzed
  • Patient anxiety will be measured on the Short ( State-Trait Anxiety Index) STAI anxiety scale pre- and post-intervention.
  • Heart rate and blood pressure will also be measured pre and post intervention.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
54

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Aug 2019

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 29, 2018

Completed
5 months until next milestone

First Posted

Study publicly available on registry

March 28, 2019

Completed
4 months until next milestone

Study Start

First participant enrolled

August 1, 2019

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 2, 2020

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2020

Completed
Last Updated

July 26, 2019

Status Verified

July 1, 2019

Enrollment Period

11 months

First QC Date

October 29, 2018

Last Update Submit

July 24, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in pain perception

    will be measured using the Visual Analogue Scale (VAS) for all subjects pre-, during and post-intervention via self-report. The scale values range from 0 to 10. ) being no pain and 10 being the worst pain

    1 year

Secondary Outcomes (4)

  • Increase or decrease in opioid/oral pain medication use

    1 year

  • Heart Rate

    1 year

  • Patient reported anxiety

    1 year

  • Blood Pressure

    1 year

Study Arms (2)

Virtual Reality analgesia

ACTIVE COMPARATOR

Trauma patients in rehab unit in the participating hospital will be included in this arm if they are randomized to receive the intervention which is a virtual reality headset providing immersive interactive content in the video format

Other: Virtual reality

Control

NO INTERVENTION

Trauma patients in rehab unit in the participating hospital will be included in this arm if they are randomized to receive no intervention

Interventions

Trauma patients enrolled in the study will be offered Virtual Reality experieince per the protocol

Virtual Reality analgesia

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult with Traumatic injury on the Acute Rehab Unit
  • Adult ages 18-100
  • Adult with intact vision who can attend VR intervention
  • Adult receiving PO Medications
  • Adult with motor control of at least one arm

You may not qualify if:

  • Adult who has uncontrolled seizures more than 4 times per year
  • Adult who is not attentive to VR secondary to poor concentration/poor cognition to external stimuli.
  • Adult with no volitional control of the neck and or upper extremities.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Jacobi Medical Center

The Bronx, New York, 10461, United States

RECRUITING

MeSH Terms

Conditions

Musculoskeletal PainAnxiety DisordersAccidental Injuries

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsMental DisordersWounds and Injuries

Study Officials

  • Michelle Stern, MD

    New York City Health and Hospitals Corporation

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Michelle Stern, MD

CONTACT

Ratnakar P Veeramachaneni, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Sequentially Numbered opaque sealed envelopes ( SNOSE) and an online randomization tool
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: This is a Randomized control study. The pre and post VAS scores will be rated by the patient. Randomization will be achieved using Sequentially Numbered opaque sealed envelopes ( SNOSE) and an online randomization tool. All the patients will choose one of three virtual reality experiences. 1. Passive VR Movie 2. Interactive relaxation/exploration 3. Active/Adventure experience
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 29, 2018

First Posted

March 28, 2019

Study Start

August 1, 2019

Primary Completion

July 2, 2020

Study Completion

October 1, 2020

Last Updated

July 26, 2019

Record last verified: 2019-07

Data Sharing

IPD Sharing
Will not share

Locations